Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406507 · ClinicalTrials.gov registry record · Phase 3
A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
A Phase 3 study of Paroxysmal Nocturnal Hemoglobinuria, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
- 9
- Study locations
NCT03406507: Completed Phase 3 study of Paroxysmal Nocturnal Hemoglobinuria, sponsored by Alexion Pharmaceuticals.
NCT03406507 is a Phase 3 study of Paroxysmal Nocturnal Hemoglobinuria that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 13 participants, below the 264-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03406507, a Phase 3 study of Paroxysmal Nocturnal Hemoglobinuria, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).
Primary Outcome
Blood samples for determination of ravulizumab Cmax were collected before and after administration of study drug at designated time points. Results are reported in micrograms/milliliter (μg/mL).
Conditions Studied
Interventions
- BIOLOGICAL Ravulizumab
Study Locations (9)
Other
- Clinical Trial Site - Paris
- Clinical Trial Site - Utrecht
- Clinical Trial Site - Oslo
- Clinical Trial Site - Moscow
- Clinical Trial Site - Saint Petersburg
- Clinical Trial Site - Leeds
- Clinical Trial Site - London
Georgia
- Clinical Trial Site - Atlanta
Wisconsin
- Clinical Trial Site - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2022-08-25 |
| Phase | Phase 3 |
What the finished NCT03406507 record still lists
NCT03406507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 264-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Paroxysmal Nocturnal Hemoglobinuria appearing as the primary indexed condition, and to 1 intervention - of which Ravulizumab is the first listed.
NCT03406507 lists 9 locations in 3 states (Other, Georgia, Wisconsin).
Frequently Asked Questions
What is clinical trial NCT03406507 about?
NCT03406507 is a clinical study titled "A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria". The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).
What is the current status of trial NCT03406507?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2018-02-22. Estimated completion is 2022-08-25.
What conditions does trial NCT03406507 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria.
What interventions are being tested in trial NCT03406507?
The interventions under investigation include: Ravulizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03406507?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03406507 being conducted?
This trial has 9 study locations across Georgia, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03406507's enrollment target sits among peer trials
13 14th of 14 higher than 1 of 14 other Paroxysmal Nocturnal Hemoglobinuria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paroxysmal Nocturnal Hemoglobinuria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
RECRUITING · Phase 3
-
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH
COMPLETED · Phase 3
-
Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI